

Alpár Horváth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8914011/publications.pdf>

Version: 2024-02-01

10
papers

146
citations

1163117

8
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

167
citing authors

#	ARTICLE	IF	CITATIONS
1	Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 104, 145-149.	4.0	34
2	Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort® Turbuhaler® dry powder fixed combination aerosol drug. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 371-379.	4.0	25
3	Establishment of relationships between native and inhalation device specific spirometric parameters as a step towards patient tailored inhalation device selection. <i>Respiratory Medicine</i> , 2019, 154, 133-140.	2.9	21
4	Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler® dry powder inhaler. <i>International Journal of Pharmaceutics</i> , 2017, 533, 225-235.	5.2	20
5	Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105508.	4.0	12
6	Effect of delayed pMDI actuation on the lung deposition of a fixed-dose combination aerosol drug. <i>International Journal of Pharmaceutics</i> , 2018, 547, 480-488.	5.2	10
7	Simulation and minimisation of the airway deposition of airborne bacteria. <i>Inhalation Toxicology</i> , 2009, 21, 1021-1029.	1.6	9
8	Computer modeling of airway deposition distribution of Foster® NEXThaler® and Seretide® Diskus® dry powder combination drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 88, 210-218.	4.0	9
9	Modeling of nursing care-associated airborne transmission of SARS-CoV-2 in a real-world hospital setting. <i>GeroScience</i> , 2022, , .	4.6	3
10	Do we really target the receptors? Deposition and co-deposition of ICS-LABA fixed combination drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 174, 106186.	4.0	1